In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Cited by (1,103)

Items 501–600 of 1,103

1. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma
   Avijit Majumdar, Steven A. Curley, Xifeng Wu, Powel H. Brown, Jessica Park Hwang, Kirti Shetty, Zhixing Yao, Aiwu Ruth He, Shulin Li, Lior Haim Katz et al. · 2012 · Nature Reviews Gastroenterology & Hepatology
2. Apoptotic brown adipocytes enhance energy expenditure via extracellular inosine
   Birte Niemann, Saskia Haufs-Brusberg, Laura Puetz, Martin Feickert, Michelle Y. Jaeckstein, Anne Hoffmann, Jelena Zurkovic, Markus Heine, Eva-Maria Trautmann, Christa Elisabeth Müller et al. · 2022 · Nature
3. Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis
   Eun‐Woo Lee, Min-Sik Lee, Suzanne Camus, Jaewang Ghim, Mi Ran Yang, Wonkyung Oh, Nam‐Chul Ha, David Philip Lane, Jaewhan Song · 2009 · The EMBO Journal
4. Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
   Wang, Qianyu, Shen, Xiaofei, Chen, Gang, Du, Junfeng · 2022 · Cancers
5. Functional Identification of Tumor-Suppressor Genes through an In Vivo RNA Interference Screen in a Mouse Lymphoma Model
   Anka Bric, Cornelius Miething, Carl Uli Bialucha, Claudio Scuoppo, Lars Zender, Alexander Krasnitz, Zhenyu Xuan, Johannes A. Zuber, Michael H. Wigler, James B Hicks et al. · 2009 · Cancer Cell
6. p53 Plays a Role in Mesenchymal Differentiation Programs, in a Cell Fate Dependent Manner
   Alina Molchadsky, Igor Shats, Naomi Goldfinger, Meirav Pevsner‐Fischer, Melissa Olson, Ariel Rinon, Eldad Tzahor, Guillermina Lozano, Dov Zipori, Rachel Sarig et al. · 2008 · PLoS ONE
7. p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR)
   Maya Maor-Nof, Zohar Shipony, Rodrigo Lopez-Gonzalez, Lisa Nakayama, Yong‐Jie Zhang, Julien Couthouis, Jacob A. Blum, Patricia A. Castruita, Gabriel R. Linares, Kai Ruan et al. · 2021 · Cell
8. The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future?
   Christian Bronner, Mayada Achour, Yoshimi Arima, Thierry Chataigneau, Hideyuki Saya, Valérie B. Schini‐Kerth · 2007 · Pharmacology & Therapeutics
9. Protein-peptide association kinetics beyond the seconds timescale from atomistic simulations
   Fabian Paul, Christoph Wehmeyer, Esam Tolba Abualrous, Hao Wu, Michael Crabtree, Johannes Schöneberg, Jane Clarke, Christian Freund, Thomas R. Weikl, Frank Noé · 2017 · Nature Communications
10. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?
    Steven Pennock, Luis J. Haddock, Dean Eliott, Shizuo Mukai, Andrius Kazlauskas · 2014 · Progress in Retinal and Eye Research
11. Methods for direct alkene diamination, new & old
    Sam De Jong, Daniel G. Nosal, Duncan J. Wardrop · 2012 · Tetrahedron
12. The Central Nervous System-Restricted Transcription Factor Olig2 Opposes p53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma
    Shwetal V. Mehta, Emmanuelle Huillard, Santosh Kesari, Cécile L. Maire, Diane Golebiowski, Emily P. Harrington, John A. Alberta, Michael Kane, Matthew Theisen, Keith Lloyd Ligon et al. · 2011 · Cancer Cell
13. Signalling and survival pathways in multiple myeloma
    Kurt Bommert, Ralf Christian Bargou, Thorsten Stühmer · 2006 · European Journal of Cancer
14. A Human Herpesvirus MicroRNA Inhibits p21 Expression and Attenuates p21-Mediated Cell Cycle Arrest
    Eva Gottwein, Bryan R. Cullen · 2010 · Journal of Virology
15. Current strategies to target p53 in cancer
    Fang Chen, Wenge Wang, Wafik S. El‐Deiry · 2010 · Biochemical Pharmacology
16. Wild-Type p53: Tumors Can't Stand It
    Michael B. Kastan · 2007 · Cell
17. Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
    Tom Van Maerken, Frank Speleman, Joëlle Vermeulen, Irina Lambertz, Sarah De Clercq, Els De Smet, Nurten Yigit, Vicky Coppens, Jan Philippé, Anne De Paepe et al. · 2006 · Cancer Research
18. Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression
    Beverly, Levi J., Felsher, Dean W., Capobianco, Anthony J. · 2005 · Cancer Research
19. Notch Inhibition as a Promising New Approach to Cancer Therapy
    Benjamin W. Purow · 2012 · Advances in experimental medicine and biology
20. Current developments of targeting the p53 signaling pathway for cancer treatment
    Jing Li Huang · 2020 · Pharmacology & Therapeutics
21. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
    Paola Secchiero, Elisa Barbarotto, Mario Tiribelli, Carlotta Zerbinati, Maria Grazia di Iasio, Arianna Gonelli, Francesco Cavazzini, Diana Campioni, Renato Fanin, Antonio Cuneo et al. · 2006 · Blood
22. Impaired Notch Signaling Leads to a Decrease in p53 Activity and Mitotic Catastrophe in Aged Muscle Stem Cells
    Liu, Ling, Charville, Gregory W., Cheung, Tom H., Yoo, Bryan, Santos, Pauline J., Schroeder, Matthew, Rando, Thomas A. · 2018 · Cell Stem Cell
23. Procaspase-3 Activation as an Anti-Cancer Strategy: Structure−Activity Relationship of Procaspase-Activating Compound 1 (PAC-1) and Its Cellular Co-Localization with Caspase-3
    Quinn P. Peterson, Danny Chung Hsu, David R. Goode, Chris J. Novotny, Ryan K. Totten, Paul J. Hergenrother · 2009 · Journal of Medicinal Chemistry
24. Targeting protein–protein interactions for cancer therapy
    David C. Fry, Lyubomir T. Vassilev · 2005 · Journal of Molecular Medicine
25. Proteasome system of protein degradation and processing
    Alexey V. Sorokin, E. R. Kim, Lev P. Ovchinnikov · 2009 · Biochemistry (Moscow)
26. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
    Saleh, Mansoor N., Patel, Manish R., Bauer, Todd M., Goel, Sanjay, Falchook, Gerald S., Shapiro, Geoffrey I., Chung, Ki Y., Infante, Jeffrey R., Conry, Robert M., Rabinowits, Guilherme et al. · 2021 · Clinical Cancer Research
27. Stereodivergent Direct Catalytic Asymmetric Mannich‐Type Reactions of α‐Isothiocyanato Ester with Ketimines
    Gang Lu, Tatsuhiko Yoshino, Hiroyuki Morimoto, Shigeki Matsunaga, Masakatsu Shibasaki · 2011 · Angewandte Chemie International Edition
28. Mutations at protein-protein interfaces: Small changes over big surfaces have large impacts on human health
    Harry C. Jubb, Arun Prasad Pandurangan, Meghan A. Turner, Bernardo Ochoa‐Montaño, Tom L. Blundell, David Benjamin Ascher · 2016 · Progress in Biophysics and Molecular Biology
29. Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression
    Howard Hua Yang, P. Charles Lin · 2017 · Seminars in Cancer Biology
30. Probing the Structural Requirements of Peptoids That Inhibit HDM2−p53 Interactions
    Toshiaki J. Hara, Stewart R. Durell, Michael C. Myers, Daniel H. Appella · 2006 · Journal of the American Chemical Society
31. Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity
    Zdeněk Andrysík, Matthew D. Galbraith, Anna L. Guarnieri, Sara Zaccara, Kelly D. Sullivan, Ahwan Pandey, Morgan L. MacBeth, Alberto Inga, Joaquin Maximiliano Espinosa · 2017 · Genome Research
32. Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain
    Sridevi Yadavilli, Lindsey D. Mayo, Maureen Higgins, Sonia Laı́n, Vijay K. Hegde, Walter A. Deutsch · 2009 · DNA repair
33. Therapeutics targeting p53-MDM2 interaction to induce cancer cell death
    Koo, Nayeong, Sharma, Arun K., Narayan, Satya · 2022 · International Journal of Molecular Sciences
34. Small‐Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System
    Dennis L. Buckley, Craig M. Crews · 2014 · Angewandte Chemie International Edition
35. The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents
    Canon, Jude, Osgood, Tao, Olson, Steven H., Saiki, Anne Y., Robertson, Rebecca, Yu, Dongyin, Eksterowicz, John, Ye, Qiuping, Jin, Lixia, Chen, Ada et al. · 2015 · Molecular Cancer Therapeutics
36. USP4 inhibits p53 through deubiquitinating and stabilizing ARF‐BP1
    Xinna Zhang, Franklin G. Berger, Jianhua Yang, Xiongbin Lu · 2011 · The EMBO Journal
37. An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase
    Stephen M. Orlicky, Xiaojing Tang, Victor Neduva, Nadine H. Elowe, Eric D. Brown, Frank Sicheri, Mike Tyers · 2010 · Nature Biotechnology
38. Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein−Protein Interaction: Structure−Activity Studies Leading to Improved Potency
    Ian Robert Hardcastle, Junfeng Liu, Eric Valeur, Anna F. Watson, Shafiq Uddin Ahmed, Timothy J. Blackburn, Karim Bennaceur, W. Clegg, Catherine J. Drummond, Jane Endicott et al. · 2011 · Journal of Medicinal Chemistry
39. Evaluation of Diverse α/β-Backbone Patterns for Functional α-Helix Mimicry: Analogues of the Bim BH3 Domain
    Melissa Boersma, Holly S. Haase, Kimberly J. Peterson‐Kaufman, Erinna F. Lee, Oliver B. Clarke, Peter M. Colman, Brian James Smith, W. Seth Horne, Walter Douglas Fairlie, Samuel H. Gellman · 2011 · Journal of the American Chemical Society
40. p53‐repressed miRNAs are involved with E2F in a feed‐forward loop promoting proliferation
    Ran Brosh, Reut Shalgi, Atar Liran, Gilad Landan, Katya Korotayev, Giang Huong Nguyen, Espen Enerly, Hilde Johnsen, Yosef Buganim, Hilla Solomon et al. · 2008 · Molecular Systems Biology
41. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression
    Ivano Amelio, Gerry Melino · 2015 · Trends in Biochemical Sciences
42. Peptide and small molecule inhibitors of HECT-type ubiquitin ligases
    Thomas Mund, Michael Lewis, Sarah Maslen, Hugh R.B. Pelham · 2014 · Proceedings of the National Academy of Sciences
43. p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome
    Benjamin T. Spike, Geoffrey M. Wahl · 2011 · Genes & Cancer
44. p53 and metabolism: from mechanism to therapeutics
    Fernando Moreira Simabuco, Mirian Galliote Morale, Isadora Carolina Betim Pavan, Ana Paula Morelli, Fernando Riback Silva, Rodrigo Esaki Tamura · 2018 · Oncotarget
45. Multicomponent Synthesis of 2-Imidazolines
    Robin S. Bon, Bart van Vliet, Nanda E. Sprenkels, Robert F. Schmitz, Frans J. J. de Kanter, Christian Victor Stevens, Marcel Swart, F. Matthias Bickelhaupt, Marinus B. Groen, Romano V. A. Orrù · 2005 · The Journal of Organic Chemistry
46. The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP
    Fiamma Mantovani, Francesca Tocco, Javier E. Girardini, Paul Smith, Milena Gasco, Xin Lü, Tim Crook, Giannino Del Sal · 2007 · Nature Structural & Molecular Biology
47. Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
    Subhasree Ashok Nag, X. Zhang, Kalkunte S. Srivenugopal, M.-H. Wang, W. Wang, Ruifeng Zhang · 2014 · Current Medicinal Chemistry
48. Resistance mechanisms to cancer chemotherapy
    Kelly M. Redmond · 2008 · Frontiers in bioscience
49. The regulation of cellular metabolism by tumor suppressor p53
    Yingjian Liang, Juan Liu, Zhaohui Feng · 2013 · Cell & Bioscience
50. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation
    Aimo Kannt, Ivan Đikić · 2021 · Cell chemical biology
51. Structural Details on mdm2-p53 Interaction
    Seung‐Wook Chi, Si‐Hyung Lee, Do‐Hyoung Kim, Min-Jung Ahn, Kim Js, Jin-Young Woo, Takuya Torizawa, Masatsune Kainosho, Kyou‐Hoon Han · 2005 · Journal of Biological Chemistry
52. The C terminus of p53 binds the N-terminal domain of MDM2
    Masha V. Poyurovsky, Chen Katz, Oleg Laptenko, Rachel Beckerman, Maria Lokshin, Jinwoo Ahn, In‐Ja L. Byeon, Ronen Gabizon, Melissa Mattia, Andrew Zupnick et al. · 2010 · Nature Structural & Molecular Biology
53. Bardoxolone conjugation enables targeted protein degradation of BRD4
    Bingqi Tong, Mai Luo, Yi Xie, Jessica N. Spradlin, John A. Tallarico, Jeffrey M. McKenna, Markus Schirle, Thomas J. Maimone, Daniel K. Nomura · 2020 · Scientific Reports
54. The Toll-like receptor gene family is integrated into human DNA damage and p53 networks
    Menendez, Daniel, Shatz, Maria, Azzam, Kathleen, Garantziotis, Stavros, Fessler, Michael B., Resnick, Michael A. · 2011 · PLoS Genetics
55. Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2−Tumor Protein 53 Protein−Protein Interaction
    John G. Allen, Matthew P. Bourbeau, G. Erich Wohlhieter, Michael D. Bartberger, Klaus Michelsen, Randall W. Hungate, Robert C. Gadwood, Rick D. Gaston, Bruce Evans, Larry W. Mann et al. · 2009 · Journal of Medicinal Chemistry
56. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
    Lars‐Gunnar Larsson · 2011 · Seminars in Cancer Biology
57. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study
    Rishi Ramesh Lulla, Stewart Goldman, Tohru Yamada, Craig W. Beattie, Linda R. Bressler, Michael Pacini, Ian F. Pollack, Paul Graham Fisher, Roger J. Packer, Ira J. Dunkel et al. · 2016 · Neuro-Oncology
58. EGCG binds intrinsically disordered N-terminal domain of p53 and disrupts p53-MDM2 interaction
    Jing Zhao, Alan J. Blayney, Xiaorong Liu, Lauren A. Gandy, Weihua Jin, Lufeng Yan, Jeung‐Hoi Ha, Ashley J. Canning, Michael Connelly, Chao Yang et al. · 2021 · Nature Communications
59. Small-Molecule Inhibitors of the MDM2-p53 Protein−Protein Interaction Based on an Isoindolinone Scaffold
    Ian Robert Hardcastle, Shafiq Uddin Ahmed, Helen Atkins, Gillian Farnie, Bernard T. Golding, Roger J. Griffin, Sabrina Guyenne, Claire Hutton, Per Källblad, Stuart J. Kemp et al. · 2006 · Journal of Medicinal Chemistry
60. Human Immunodeficiency Virus Protein Tat Induces Synapse Loss via a Reversible Process That Is Distinct from Cell Death
    Hee Jung Kim, Kirill A. Martemyanov, Stanley A. Thayer · 2008 · Journal of Neuroscience
61. An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours
    Pieter Mestdagh, Erik Fredlund, Filip Pattyn, Ali Rihani, Tom Van Maerken, Joëlle Vermeulen, Candy Kumps, Björn Menten, Katleen De Preter, Alexander R. Schramm et al. · 2010 · Oncogene
62. Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
    Hong Shen, Carl G. Maki · 2011 · Current Pharmaceutical Design
63. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
    Daniel R. Carter, Jayne E. Murray, Belamy B. Cheung, Laura D. Gamble, Jessica Koach, Joanna Tsang, Selina K. Sutton, Heyam Kalla, Sarah Syed, Andrew J. Gifford et al. · 2015 · Science Translational Medicine
64. Carbodiimide-based synthesis of N-heterocycles: moving from two classical reactive sites to chemical bond breaking/forming reaction
    Yang Wang, Wen‐Xiong Zhang, Zhenfeng Xi · 2020 · Chemical Society Reviews
65. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways
    Anwesha Dey, Vinay Tergaonkar, David Philip Lane · 2008 · Nature Reviews Drug Discovery
66. The p53–Mdm2–HAUSP complex is involved in p53 stabilization by HAUSP
    Christopher L. Brooks, M Li, M Hu, Yigong Shi, Wei Gu · 2007 · Oncogene
67. Targeting the ubiquitin pathway for cancer treatment
    Jia Liu, Shavali Shaik, Xiangpeng Dai, Qiong Wu, Xiuxia Zhou, Zhiwei Peter Wang, Wenyi Wei · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
68. The role of telomeres and telomerase in stem cell aging
    Flores, Ignacio, Blasco, Maria A. · 2010 · FEBS Letters
69. Trapping Moving Targets with Small Molecules
    Gregory Lee, Charles S. Craik · 2009 · Science
70. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
    Wei Wang, Najah G. Albadari, Yi Du, Josef F. Fowler, Hannah T. Sang, Wa Xian, Frank McKeon, Wěi Li, Jia Zhou, Ruiwen Zhang · 2024 · Pharmacological Reviews
71. The Lysine-specific Demethylase 1 Is Required for Cell Proliferation in Both p53-dependent and -independent Manners
    Ariane Scoumanne, Xinbin Chen · 2007 · Journal of Biological Chemistry
72. Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions
    Chong V. Li, Marzena Pazgier, Changqing Li, Weirong Yuan, Min Liu, Gang Wei, Weiyue Lu, Wuyuan Lu · 2010 · Journal of Molecular Biology
73. Design, Synthesis, and Evaluation of an α-Helix Mimetic Library Targeting Protein−Protein Interactions
    Alex Shaginian, Landon R. Whitby, Sukwon Hong, Inkyu Hwang, Bilal Farooqi, Mark Searcey, Jiandong Chen, Peter K. Vogt, Dale L. Boger · 2009 · Journal of the American Chemical Society
74. A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells
    Kyoung Hwa Lee, Mangmang Li, Aleksandra M. Michalowski, Xinyue Zhang, Hongling Liao, Lingyi Chen, Yang Xu, Xiaolin Wu, Jing Li Huang · 2009 · Proceedings of the National Academy of Sciences
75. Degrons in cancer
    Bálint Mészáros, Manjeet Kumar, Toby J. Gibson, Bora Uyar, Zsuzsanna Dosztányi · 2017 · Science Signaling
76. The Human TLR Innate Immune Gene Family Is Differentially Influenced by DNA Stress and p53 Status in Cancer Cells
    Shatz, Maria, Menendez, Daniel, Resnick, Michael A. · 2012 · Cancer Research
77. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death
    Eveline Barbieri, Parth S. Mehta, Zaowen Chen, Linna Zhang, Andrew Slack, Stacey L. Berg, Jason Matthew Shohet · 2006 · Molecular Cancer Therapeutics
78. Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast Origin
    Efeyan, Alejo, Ortega-Molina, Ana, Velasco-Miguel, Susana, Herranz, Daniel, Vassilev, Lyubomir T., Serrano, Manuel · 2007 · Cancer Research
79. Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D2concept
    Vladimir Nikolaevich Uversky · 2010 · Expert Review of Proteomics
80. Estrogen receptor prevents p53-dependent apoptosis in breast cancer
    Shannon Terrell Bailey, Hyunjin Shin, Thomas Westerling, Xiaole Shirley Liu, Myles A Brown · 2012 · Proceedings of the National Academy of Sciences
81. Massively regulated genes: the example of TP53
    Monica C. Hollstein, Pierre L. Hainaut · 2009 · The Journal of Pathology
82. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma
    Wolfgang Wick, Susan Dettmer, Anne Berberich, Tobias Keßler, Irini Karapanagiotou‐Schenkel, Antje Wick, Frank Winkler, Elke Pfaff, Benedikt Brors, Jürgen Debus et al. · 2018 · Neuro-Oncology
83. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells
    Rosa Puca, Lavinia Nardinocchi, David Givol, Gabriella D’Orazi · 2010 · Oncogene
84. Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction
    Jeffrey P. Plante, Thomas Burnley, Barbora Malkova, Michael E. Webb, Stuart L. Warriner, Thomas A. Edwards, Andrew John Wilson · 2009 · Chemical Communications
85. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
    Klas G. Wiman · 2010 · Oncogene
86. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas
    Grzegorz Sarek, Sari Kurki, Juulia Enbäck, Guergana Iotzova, Juergen Haas, Pirjo Laakkonen, Marikki Laiho, Päivi M. Ojala · 2007 · Journal of Clinical Investigation
87. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis
    Anni I. Nieminen, Vilja Eskelinen, Heidi M. Haikala, Topi Aulis Tervonen, Yan Yan, Johanna I. Partanen, Juha T. Klefström · 2013 · Proceedings of the National Academy of Sciences
88. Hot-spot mimicry of a cytokine receptor by a small molecule
    Christopher D. Thanos, Warren L. DeLano, James A. Wells · 2006 · Proceedings of the National Academy of Sciences
89. Regulation of p53: a collaboration between Mdm2 and MdmX
    Pei, Dongsheng, Zhang, Yanping, Zheng, Junnian · 2012 · Oncotarget
90. Structure of Free MDM2 N-terminal Domain Reveals Conformational Adjustments that Accompany p53-binding
    Stanislava Uhrı́nová, Dušan Uhrı́n, Helen Powers, Kathryn Watt, Daniella I. Zheleva, Peter M. Fischer, Campbell McInnes, Paul Nigel Barlow · 2005 · Journal of Molecular Biology
91. One, two, three—p53, p63, p73 and chemosensitivity
    M MULLER, Elisa Schulze Schleithoff, Wolfgang Stremmel, Gerry Melino, Peter H. Krammer, Tobias Schilling · 2006 · Drug Resistance Updates
92. The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor
    Valérie M. Renault, Pramod U. Thekkat, Kimmi Hoang, Jamie L. White, Colleen A. Brady, Daniela Kenzelmann Brož, O S Venturelli, T M Johnson, Philip R. Oskoui, Zhenyu Xuan et al. · 2011 · Oncogene
93. p73 in Cancer
    Alessandro Rufini, Massimiliano Agostini, Francesca Grespi, Richard Tomasini, Berna S. Sayan, Maria Victoria Niklison-Chirou, Franco Conforti, Tania Velletri, Antonio Mastino, Tak W. Mak et al. · 2011 · Genes & Cancer
94. Translational applications of adult stem cell-derived organoids
    Jarno Drost, Hans C. Clevers · 2017 · Development
95. Stereodivergent Direct Catalytic Asymmetric Mannich‐Type Reactions of α‐Isothiocyanato Ester with Ketimines
    Gang Lü, Tatsuhiko Yoshino, Hiroyuki Morimoto, Shigeki Matsunaga, Masakatsu Shibasaki · 2011 · Angewandte Chemie
96. The central region of HDM2 provides a second binding site for p53
    Grace W. Yu, Stefan Rüdiger, Dmitry B. Veprintsev, Stefan M.V. Freund, Marı́a Rosario Fernández-Fernández, Alan Roy Fersht · 2006 · Proceedings of the National Academy of Sciences
97. TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway
    L-H Zhang, Anan Yin, Cheng Jx, H-Y Huang, Li Xm, Y-Q Zhang, N Han, Xiang Zhang · 2014 · Oncogene
98. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture
    Pasha Apontes, Olga V. Leontieva, Zoya N. Demidenko, Fengzhi Li, Mikhail V. Blagosklonny · 2011 · Oncotarget
99. TP53 in bone and soft tissue sarcomas
    Elizabeth A. Thoenen, Amanda Curl, Tomoo Iwakuma · 2019 · Pharmacology & Therapeutics
100. Inhibition of p53 inhibitors: progress, challenges and perspectives
     Gema Sanz, Madhurendra Singh, Sylvain Peuget, Galina Selivanova · 2019 · Journal of Molecular Cell Biology